Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Nov 15;100(10):2512–2520. doi: 10.1172/JCI119793

Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.

J W Pippin 1, Q Qu 1, L Meijer 1, S J Shankland 1
PMCID: PMC508451  PMID: 9366565

Abstract

Glomerular injury is characterized by mesangial cell (MC) proliferation and matrix formation. We sought to determine if reducing the activity of cyclin-dependent kinase 2 (CDK2) with the purine analogue, Roscovitine, decreased MC proliferation in vitro and in vivo. Roscovitine (25 microM) inhibited FCS-induced proliferation (P < 0.0001) in cultured MC. Rats with experimental mesangial proliferative glomerulonephritis (Thy1 model) were divided into two groups. A prevention group received daily intraperitoneal injections of Roscovitine in DMSO (2.8 mg/kg) starting at day 1. A treatment group received daily Roscovitine starting at day 3, when MC proliferation was established. Control Thy1 rats received DMSO alone. MC proliferation (PCNA +/OX7 + double immunostaining) was reduced by > 50% at days 5 and 10 in the Roscovitine prevention group, and at day 5 in the treatment group (P < 0.0001). Early administration of Roscovitine reduced immunostaining for collagen type IV, laminin, and fibronectin at days 5 and 10 (r = 0.984; P < 0.001), which was associated with improved renal function (urinary protein/creatinine, blood urea nitrogen, P < 0.05). We conclude that reducing the activity of CDK2 with Roscovitine in experimental glomerulonephritis decreases cell proliferation and matrix production, resulting in improved renal function, and may be a useful therapeutic intervention in disease characterized by proliferation.

Full Text

The Full Text of this article is available as a PDF (412.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ando K., Ajchenbaum-Cymbalista F., Griffin J. D. Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9571–9575. doi: 10.1073/pnas.90.20.9571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baker P. J., Ochi R. F., Schulze M., Johnson R. J., Campbell C., Couser W. G. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol. 1989 Jul;135(1):185–194. [PMC free article] [PubMed] [Google Scholar]
  3. Baldin V., Lukas J., Marcote M. J., Pagano M., Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993 May;7(5):812–821. doi: 10.1101/gad.7.5.812. [DOI] [PubMed] [Google Scholar]
  4. Butler A. R. The Jaffé reaction. Identification of the coloured species. Clin Chim Acta. 1975 Mar 10;59(2):227–232. doi: 10.1016/0009-8981(75)90033-9. [DOI] [PubMed] [Google Scholar]
  5. Crocker C. L. Rapid determination of urea nitrogen in serum or plasma without deproteinization. Am J Med Technol. 1967 Sep-Oct;33(5):361–365. [PubMed] [Google Scholar]
  6. De Azevedo W. F., Leclerc S., Meijer L., Havlicek L., Strnad M., Kim S. H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem. 1997 Jan 15;243(1-2):518–526. doi: 10.1111/j.1432-1033.1997.0518a.x. [DOI] [PubMed] [Google Scholar]
  7. Draetta G. Cdc2 activation: the interplay of cyclin binding and Thr161 phosphorylation. Trends Cell Biol. 1993 Sep;3(9):287–289. doi: 10.1016/0962-8924(93)90001-h. [DOI] [PubMed] [Google Scholar]
  8. Floege J., Eng E., Young B. A., Couser W. G., Johnson R. J. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis. Kidney Int. 1993 Feb;43(2):369–380. doi: 10.1038/ki.1993.55. [DOI] [PubMed] [Google Scholar]
  9. Floege J., Johnson R. J., Gordon K., Iida H., Pritzl P., Yoshimura A., Campbell C., Alpers C. E., Couser W. G. Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int. 1991 Sep;40(3):477–488. doi: 10.1038/ki.1991.235. [DOI] [PubMed] [Google Scholar]
  10. Girard F., Strausfeld U., Fernandez A., Lamb N. J. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell. 1991 Dec 20;67(6):1169–1179. doi: 10.1016/0092-8674(91)90293-8. [DOI] [PubMed] [Google Scholar]
  11. Hugo C., Pichler R., Meek R., Gordon K., Kyriakides T., Floege J., Bornstein P., Couser W. G., Johnson R. J. Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. Kidney Int. 1995 Dec;48(6):1846–1856. doi: 10.1038/ki.1995.483. [DOI] [PubMed] [Google Scholar]
  12. Jeffrey P. D., Russo A. A., Polyak K., Gibbs E., Hurwitz J., Massagué J., Pavletich N. P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 1995 Jul 27;376(6538):313–320. doi: 10.1038/376313a0. [DOI] [PubMed] [Google Scholar]
  13. Johnson R. J., Iida H., Alpers C. E., Majesky M. W., Schwartz S. M., Pritzi P., Gordon K., Gown A. M. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest. 1991 Mar;87(3):847–858. doi: 10.1172/JCI115089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Johnson R. J., Pritzl P., Iida H., Alpers C. E. Platelet-complement interactions in mesangial proliferative nephritis in the rat. Am J Pathol. 1991 Feb;138(2):313–321. [PMC free article] [PubMed] [Google Scholar]
  15. Johnson R. J., Raines E. W., Floege J., Yoshimura A., Pritzl P., Alpers C., Ross R. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med. 1992 May 1;175(5):1413–1416. doi: 10.1084/jem.175.5.1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Johnson R. J. The glomerular response to injury: progression or resolution? Kidney Int. 1994 Jun;45(6):1769–1782. doi: 10.1038/ki.1994.230. [DOI] [PubMed] [Google Scholar]
  17. Lees E. Cyclin dependent kinase regulation. Curr Opin Cell Biol. 1995 Dec;7(6):773–780. doi: 10.1016/0955-0674(95)80060-3. [DOI] [PubMed] [Google Scholar]
  18. Meijer L., Borgne A., Mulner O., Chong J. P., Blow J. J., Inagaki N., Inagaki M., Delcros J. G., Moulinoux J. P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997 Jan 15;243(1-2):527–536. doi: 10.1111/j.1432-1033.1997.t01-2-00527.x. [DOI] [PubMed] [Google Scholar]
  19. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Prog Cell Cycle Res. 1995;1:351–363. doi: 10.1007/978-1-4615-1809-9_29. [DOI] [PubMed] [Google Scholar]
  20. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol. 1996 Oct;6(10):393–397. doi: 10.1016/0962-8924(96)10034-9. [DOI] [PubMed] [Google Scholar]
  21. Morishita R., Gibbons G. H., Ellison K. E., Nakajima M., von der Leyen H., Zhang L., Kaneda Y., Ogihara T., Dzau V. J. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994 Apr;93(4):1458–1464. doi: 10.1172/JCI117123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nelson R. A., Jr, Jensen J., Gigli I., Tamura N. Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry. 1966 Mar;3(2):111–135. doi: 10.1016/0019-2791(66)90292-8. [DOI] [PubMed] [Google Scholar]
  23. Ohtsubo M., Theodoras A. M., Schumacher J., Roberts J. M., Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol. 1995 May;15(5):2612–2624. doi: 10.1128/mcb.15.5.2612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shankland S. J., Hugo C., Coats S. R., Nangaku M., Pichler R. H., Gordon K. L., Pippin J., Roberts J. M., Couser W. G., Johnson R. J. Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis. Kidney Int. 1996 Oct;50(4):1230–1239. doi: 10.1038/ki.1996.432. [DOI] [PubMed] [Google Scholar]
  25. Shankland S. J., Pippin J., Flanagan M., Coats S. R., Nangaku M., Gordon K. L., Roberts J. M., Couser W. G., Johnson R. J. Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int. 1997 Apr;51(4):1088–1099. doi: 10.1038/ki.1997.151. [DOI] [PubMed] [Google Scholar]
  26. Sherr C. J. Cancer cell cycles. Science. 1996 Dec 6;274(5293):1672–1677. doi: 10.1126/science.274.5293.1672. [DOI] [PubMed] [Google Scholar]
  27. Sherr C. J. Mammalian G1 cyclins. Cell. 1993 Jun 18;73(6):1059–1065. doi: 10.1016/0092-8674(93)90636-5. [DOI] [PubMed] [Google Scholar]
  28. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149–1163. doi: 10.1101/gad.9.10.1149. [DOI] [PubMed] [Google Scholar]
  29. Suzuki J., Isobe M., Morishita R., Aoki M., Horie S., Okubo Y., Kaneda Y., Sawa Y., Matsuda H., Ogihara T. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med. 1997 Aug;3(8):900–903. doi: 10.1038/nm0897-900. [DOI] [PubMed] [Google Scholar]
  30. Tsai L. H., Lees E., Faha B., Harlow E., Riabowol K. The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene. 1993 Jun;8(6):1593–1602. [PubMed] [Google Scholar]
  31. Tsuboi Y., Shankland S. J., Grande J. P., Walker H. J., Johnson R. J., Dousa T. P. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. J Clin Invest. 1996 Jul 15;98(2):262–270. doi: 10.1172/JCI118788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Veselý J., Havlicek L., Strnad M., Blow J. J., Donella-Deana A., Pinna L., Letham D. S., Kato J., Detivaud L., Leclerc S. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem. 1994 Sep 1;224(2):771–786. doi: 10.1111/j.1432-1033.1994.00771.x. [DOI] [PubMed] [Google Scholar]
  33. Wagner R. W. Gene inhibition using antisense oligodeoxynucleotides. Nature. 1994 Nov 24;372(6504):333–335. doi: 10.1038/372333a0. [DOI] [PubMed] [Google Scholar]
  34. Wagner R. W. The state of the art in antisense research. Nat Med. 1995 Nov;1(11):1116–1118. doi: 10.1038/nm1195-1116. [DOI] [PubMed] [Google Scholar]
  35. Yamamoto T., Wilson C. B. Complement dependence of antibody-induced mesangial cell injury in the rat. J Immunol. 1987 Jun 1;138(11):3758–3765. [PubMed] [Google Scholar]
  36. Yamamoto T., Wilson C. B. Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. Kidney Int. 1987 Oct;32(4):514–525. doi: 10.1038/ki.1987.240. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES